Valiloxybate
Excessive Daytime Somnolence
XWPharmaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Excessive Daytime Somnolence cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Solriamfetol Duke University | Phase 2 | BB |
CAFFEINE Ron Postuma | Phase 2/3 | B |
Modafinil Duke University | Phase 2 | B |
MELATONIN Duke University | Phase 2 | B |
.GAMMA.-HYDROXYBUTYRATE SODIUM SALT Brigham and Women's Hospital | Early Phase 1 | C |
Gate-101 Syndeio Biosciences, Inc | Phase 1 | NR |
Same molecule, other indications
Valiloxybate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →